10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.622.0609

Kallikrein 7 Antibody (C-term) Blocking peptide

Synthetic peptide
Catalog # BP6326b

Specification

Kallikrein 7 Antibody (C-term) Blocking peptide - Product Information

Primary Accession P49862

Kallikrein 7 Antibody (C-term) Blocking peptide - Additional Information

Gene ID 5650

Other Names
Kallikrein-7, hK7, Serine protease 6, Stratum corneum chymotryptic enzyme, hSCCE, KLK7, PRSS6, SCCE

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP6326b was selected from the C-term region of human KLK7. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

Kallikrein 7 Antibody (C-term) Blocking peptide - Protein Information

Name KLK7

Kallikrein 7 Antibody (C-term) Blocking peptide - Background

Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. The KLK7 enzyme is thought to be involved in the proteolysis of intercellular cohesive structures preceding desquamation, which is the shedding of the outermost layer of the epidermis.

Kallikrein 7 Antibody (C-term) Blocking peptide - References

Planque, C., et al., Biochem. Biophys. Res. Commun. 329(4):1260-1266 (2005).Ishida-Yamamoto, A., et al., J. Invest. Dermatol. 124(2):360-366 (2005).Vasilopoulos, Y., et al., J. Invest. Dermatol. 123(1):62-66 (2004).Santin, A.D., et al., Gynecol. Oncol. 94(2):283-288 (2004).Caubet, C., et al., J. Invest. Dermatol. 122(5):1235-1244 (2004).

Synonyms PRSS6, SCCE

Function
May catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. Specific for amino acid residues with aromatic side chains in the P1 position. Cleaves insulin A chain at '14-Tyr-|-Gln-15' and insulin B chain at '6-Leu-|-Cys-7', '16-Tyr-|-Leu-17', '25-Phe-|-Tyr-26' and '26-Tyr-|-Thr-27'. Could play a role in the activation of precursors to inflammatory cytokines.

Cellular Location
Secreted. Note=In ovarian carcinoma, secreted and also observed at the apical membrane and in cytoplasm at the invasive front

Tissue Location
Abundantly expressed in the skin and is expressed by keratinocytes in the epidermis. Also expressed in the brain, mammary gland, cerebellum, spinal cord and kidney. Lower levels in salivary glands, uterus, thymus, thyroid, placenta, trachea and testis. Up- regulated in ovarian carcinoma, especially late-stage serous carcinoma, compared with normal ovaries and benign adenomas (at protein level)

Kallikrein 7 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides